Peripheral T-cell lymphomas (PTCLs) are a group of rare, aggressive non-Hodgkin lymphomas (NHLs) originating from post-thymic or mature T cells and natural killer (NK) cells.1 PTCLs account for ~10% of new NHL cases, equating to 8,000-12,000 new PTCL cases in the US in 2020.2,3 The World Health Organization has described >25 different types of PTCLs, and distinct molecular signatures are being investigated to identify candidates for targeted treatments.3 CD30 is universally expressed in systemic anaplastic large cell lymphoma (sALCL) and expressed in ~50% of non-sALCL subtypes.4,5. The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.